Synapse
⌘+K
Synapse
PulseExploreClubsResearchersJournals
Instagram
HomeClubsExplore
May 15, 2026Alimentary Pharmacology & Therapeutics

Letter: Unmasking the Risks—The Need for Robust Data on Baclofen in Cirrhotic Patients. Authors' Reply

View Full Paper
Ask AI
Bookmark
Share

Authors

YYYee Hui YeoJAJuan Pablo ArabLLLorenzo Leggio

Discussion

Loading...

Member takes

Overview

Authors reveal safety differences of baclofen and acamprosate in cirrhotic patients with AUD, suggesting tailored treatment approaches.

Key Points

  • This study aims to provide safety data comparing baclofen and acamprosate in patients with alcohol use disorder and cirrhosis.
  • Real-world comparative analysis of baclofen and acamprosate safety in cirrhotic patients.
  • Assessment of hepatic encephalopathy risk associated with each medication.
  • Consideration of patient-specific factors like comorbidities and prior encephalopathy.
  • Acamprosate is associated with a lower risk of hepatic encephalopathy compared to baclofen in higher-risk patients.
  • Baclofen remains an endorsed therapy for alcohol use disorder despite safety concerns.
  • Further prospective studies are recommended to better understand individual treatment responses.

Cite This Study

Yeo et al. (2026) studied this question.

synapsesocial.com/papers/6a06b940e7dec685947abd6fhttps://doi.org/10.1111/apt.70709
View Full Paper
Ask AI
Bookmark
Share